Apalutamide is indicated for adult men for the treatment of metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||26/02/2020|
|Rapid review completed||23/03/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of apalutamide for this indication compared with the current standard of care.|